Interventions for structural heart disease

Thirty-day VARC-2 and performance data of a new self-expanding transcatheter aortic heart valve

EuroIntervention 2015;10:785-792 published online ahead of aprint May 2015. DOI: 10.4244/EIJY15M05_05

Hendrik Treede
Hendrik Treede1*, MD; Edith Lubos2, MD; Lenard Conradi1, MD; Florian Deuschl2, MD; Federico M. Asch3, MD; Neil J. Weissman3, MD; Niklas Schofer2, MD; Johannes Schirmer1, MD; Dietmar Koschyk2, MD; Stefan Blankenberg2, MD; Hermann Reichenspurner1, MD, PhD; Ulrich Schaefer2, MD
1. Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; 2. Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany; 3. MedStar Cardiovascular Research Network at Washington

Aims: Transcatheter aortic valve therapy has become an established procedure for patients at high risk for surgical valve replacement. The BIOVALVE-I study aims to assess the safety and p

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

aortic stenosisbiovalvenitinolself-expandingtranscatheter heart valvetransfemoral
Read next article
“Heart Team” decision making in elderly patients with symptomatic aortic valve stenosis who underwent AVR or TAVI – a look behind the curtain. Results of the prospective TAVI Calculation of Costs Trial (TCCT)

Latest news